High Risk Smoldering Myeloma Discussed on CureTalks in 2016 – A Quick Recap

High risk smoldering myeloma was discussed in a three part series on CureTalks in 2016. The myeloma panel of myeloma advocates Gary Petersen, Jack Aiello, Cynthia Chmielewski, Yelak Biru and Matt Goldman addressed nuances of high risk smoldering myeloma treatments, difference between high risk myeloma and high risk smoldering myeloma, new trials and more with international myeloma experts.

A quick recap below:

Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma Patients with Dr. Shaji Kumar

 

smoldering-myeloma dr. shaji kumar

This was the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. High risk SMM patients carry a high risk to progression to multiple myeloma. High risk SMM has been recognised as the optimal phase to test early treatment strategies. The ASCENT trial aims to prevent progression to active myeloma by 30-50% in the high risk to progression SMM patients. We talked to Dr. Shaji Kumar Principal Investigator of the trial and Mayo Clinic expert.

Catch the nuances of the ASCENT trial with Dr. Kumar HERE!

History and Future Initiatives for High Risk Smoldering Myeloma Cure with Prof. Jesus San Miguel

 

smoldering myeloma

For this second talk in our high risk smoldering myeloma series, we had Prof. Jesus San Miguel from University of Navarra, Spain discuss his team’s investigations into high-risk smoldering myeloma and probable cure. For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention.

Catch Prof. Jesus San Miguel talk about his research, clinical trials in the pipeline and future of myeloma treatment HERE!

 

Understanding iSTOPMM: Iceland Screens, Treats, or Prevents Multiple Myeloma with Dr. Sigurour Yngvi Kristinsson

 

istopmm

iStopMM initiative may be one of most important events in modern day myeloma care. As part of the iStopMM study, 140,000 Icelanders over the age of 40 will have their blood samples tested for the precursor to multiple myeloma, or MGUS (monoclonal gammopathy of undetermined significance).

Listen to Dr. Siguror Kristinsson of the University of Iceland discuss this exciting and groundbreaking study with us HERE!

Stay tuned as we continue to bring international experts to discuss latest in research and treatments. 

About the Author

Leave a Reply

Your email address will not be published. Required fields are marked *